Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study

NCT05909501 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT05909501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05909501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AGE-ING (Assessment of Geriatric Evaluations Impact on New AML Guidance) Study
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Observational
Overall status
Recruiting
Start date
October 25, 2023
Completion date
December 1, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, adult